NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression - Argus Press

Submitted by Anonymous (not verified) on Thu, 12/13/2018 - 12:02

NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression  Argus PressWILMINGTON, Del.--(BUSINESS WIRE)--Dec 13, 2018--NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting ...